Dis-Chem raises R1.1bn but sentiment sours on news of executive sales
CEO Ivan Saltzman, executive Stan Goetsch and director Niall Hegarty sold 32-million shares
Pharmacy group Dis-Chem has raised R1.1bn to fund its expansion, but the news failed to impress shareholders. The company’s share price dropped as much as 14% after it disclosed the details of its capital-raising programme. Dis-Chem chief financial director Rui Morais said the capital raised was a “wealth diversification method” for some of the original shareholders. As part of the bookbuild, senior Dis-Chem executives Ivan Saltzman, Stan Goetsch and Niall Hegarty sold altogether 32-million ordinary shares at R35 per share. After the transaction Saltzman, Goetsch and Hegarty own 52.7%, 6% and 3.2%, respectively, in Dis-Chem. Investment analyst at Sanlam Private Wealth Renier de Bruyn said that given the size and liquidity of the company, it was an astute move for Dis-Chem to conduct such a capital raise. Equity analyst at JM Busha Group Simbarashe Chimanzi concurred, saying that the accelerated bookbuild was necessary as it opened free float and added liquidity to the share, but the...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.